Ryvu Therapeutics Equity 2024

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Ryvu Therapeutics's Equity

Ryvu Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ryvu Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ryvu Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ryvu Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ryvu Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ryvu Therapeutics stock

What is the equity of Ryvu Therapeutics this year?

Ryvu Therapeutics has equity of 259.59 M PLN this year.

What was the equity of Ryvu Therapeutics compared to the previous year?

The equity of Ryvu Therapeutics has increased/decreased by -24.4% decreased compared to the previous year.

What impact does a high equity have on investors of Ryvu Therapeutics?

A high equity is advantageous for investors of Ryvu Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Ryvu Therapeutics?

A low equity can be a risk for investors of Ryvu Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Ryvu Therapeutics affect the company?

An increase in equity of Ryvu Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Ryvu Therapeutics affect the company?

A reduction in equity of Ryvu Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Ryvu Therapeutics?

Some factors that can affect the equity of Ryvu Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Ryvu Therapeutics so important for investors?

The equity of Ryvu Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Ryvu Therapeutics take to change the equity?

To change equity, Ryvu Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 10/28/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.